Daiichi Sankyo Company, Limited announced that it will present new research data across its DXd ADC portfolio including ENHERTU® (trastuzumab deruxtecan), datopotamab deruxtecan (Dato-DXd; DS-1062) and patritumab deruxtecan (HER3-DXd) at the 2020 World Conference on Lung Cancer (#WCLC20) virtual conference to be held January 28-31, 2021. Interim results from the pivotal phase 2 DESTINY-Lung01 trial of ENHERTU, a HER2 directed ADC, from the HER2 overexpressing metastatic NSCLC cohort will be featured as a late-breaking oral presentation. Encore results from the HER2 mutant metastatic NSCLC cohort of DESTINY-Lung01, which were previously presented at the 2020 American Society of Clinical Oncology (ASCO) virtual meeting, will also be presented. Updated research data from the NSCLC cohort of the TROPION-PanTumor01 study of datopotamab deruxtecan, a TROP2 directed ADC, will be presented, highlighting data that includes additional patients in both the dose escalation and dose expansion parts of the study. A new biomarker analysis from an ongoing phase 1 study of patritumab deruxtecan, a HER3 directed ADC, will provide initial observations of HER3 expression and its association with prior treatment in patients with previously treated metastatic or locally advanced epidermal growth factor receptor-mutated (EGFR mutated) NSCLC. Encore clinical results from the phase 1 study, which were previously presented at the 2020 European Society of Clinical Oncology (ESMO) virtual meeting, will also be presented. Trial-in-progress updates from the phase 1b study of ENHERTU in combination with pembrolizumab, HERTHENA-Lung01, a phase 2 study of patritumab deruxtecan in patients with previously treated metastatic or locally advanced EGFR mutated NSCLC, and a phase 1 study of patritumab deruxtecan in combination with osimertinib in patients with locally advanced or metastatic EGFR mutant NSCLC will also be presented.